Select a cancer type to view all clinical trials for that cancer, or view all currently open clinical trials below.
All Current Clinical Trials
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | Clinical.Trials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| PSMA-007-001 | Castrate-Resistant Prostate Cancer | A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer | Immunotherapy | PSMA targeting BiTE. | Open - Recruiting | Janux Therapeutics | NCT05519449 | Enquire Now |
| GRWD5769-ST-01 | Multi-Cancers | A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination With Anticancer Treatments in Patients With Solid Malignancies | Immunotherapy | Novel EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial – 1) | Open - Recruiting | Grey Wolf Therapeutics Pty Ltd | NCT06923761 | Enquire Now |
| AWT020-001 | Multi-Cancers | A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients With Progressive Locally Advanced or Metastatic Cancer | Immunotherapy | Anti-PD1 IL-2 BiTE. | Open - Recruiting | Anwita Biosciences | NCT06092580 | Enquire Now |
| CP-AU-007-01 | Multi-Cancers | A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Immunotherapy | IL-2 and Inhibits IL-2Rα Binding in combo. | Open - Recruiting | Aulos Bioscience, Inc. | NCT05267626 | Enquire Now |
| HMBD-001-103 | Multi-Cancers | A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination With Cetuximab in Participants With Advanced Squamous Cell Cancers | Targeted | Humanized IgG1 anti-HER3 monoclonal antibody + Combo treatment for squamous HER3 Mutation. | Open - Recruiting | Hummingbird Bioscience | NCT05910827 | Enquire Now |
| PTT-4256-01 | Multi-Cancers | A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256. | Immunotherapy | Inhibitor of the pH-sensing G-protein-coupled receptor 65 | Open - Recruiting | Pathios Therapeutics Pty Ltd | NCT06634849 | Enquire Now |
| ADCE-T02-01 | Multi-Cancers | First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting a tissue factor. | Open - Recruiting | Adcendo ApS | NCT06597721 | Enquire Now |
| CP-IVX001 | Multi-Cancers | A Phase 1 Open-label, Non-randomized, Multi-cohort Clinical Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | Injectable Lesions | Ovarian, Gastric and CRC only. Must have Injectable lesions. Intratumoral injection. Live EchoVirus, No GMO component. | Open - Recruiting | ImmVirx PtyLtd | NCT05427487 | Enquire Now |
| BI - 1456-0001 | Multi-Cancers | A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | Immunotherapy | Genetically Modified Virus | Open - Recruiting | Boehringer Ingelheim | NCT05155332 | Enquire Now |
| DM002001 | Multi-Cancers | A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting MUC1 and HER3 | Open - Recruiting | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | NCT06751329 | Enquire Now |
| HRS-5041-103 | Prostate Cancer | A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer | Targeted | AR-PROTAC molecule - AR degrader | Open - Recruiting | Atridia Pty Ltd | NCT06830850 | Enquire Now |
| VRN110755 | Non-Small Cell Lung Cancer (NSCLC) | A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) | Targeted | Small molecule EGFR inhibitor for EGFR-mutated NSCLC | Open - Recruiting | Voronoi Therapeutics | TBA | Enquire Now |
| GIANTS-1 | Cancer Survivors | A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors (GIANTS-1) | Immunotherapy | Bispecific immunocytokine composed of CD80 fused with a mutated interleukin (IL)-2. In combo with probiotic. | Open - Recruiting | GI Innovation, Inc. | NCT07363057 | Enquire Now |
| SP-03-B101 | Multi-Cancers | A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Sapu003 in Combination with Exemestane in Patients with Advanced mTOR-sensitive solid tumors (HR+/HER2- Br Ca, RCC, NETs, TSC, HCC) | Targeted | Intravenous Everolimus. HR+ HER2- breast, HCC, RCC, NETs TSC- associated tumours | Open - Recruiting | Sapu Bioscience | ACTRN12625001083482 | Enquire Now |
| ADCE-B05-001 | Multi-Cancers | A First-in-Human, Phase 1a/1b, Open-Label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of the Antibody Drug Conjugate ADCE-B05 in Patients with Advanced Solid Tumors | Immunotherapy | ADC anti-GPC1 IgG1 with a Topo-I inhibitor and P1021 | Open - Recruiting | Adcendo ApS | NCT07362888 | Enquire Now |
| HDM2017-101 | Multi-Cancers | A Phase 1 Study of HDM2017 in Advanced Solid Tumors | Targeted | ADC targeting CDH17 conjugated to CPT-derivative payloads | Open - Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT07274085 | Enquire Now |